Investigation of Plasma IP-10 During Treatment of Pulmonary Tuberculosis
Year: 2015
Type: article
Abstract: Background. Monitoring response to anti-tuberculosis treatment (ATT) in patients with pulmonary tuberculosis (PTB) requires detection of Mycobacterium tuberculosis (Mtb) in sputum. However, current methods are suboptimal due to the poor performance of the sputum smear test and the long duration (3-6 weeks) required for culturing Mtb. We hypothesized that plamsa levels of Interferon-induced Protein-10 (IP-10), a chemokine secreted primarily by monocytes, would decrease with ATT and may be useful a plasma biomarker of ATT. While plasma-based soluble markers are not pathogen specific, they can be easily and affordably measured by enzyme-linked immunosorbent assays (ELISAs) and could complement sputum-based assessments. We sought to measure the levels of IP-10 in the plasma of patients with PTB, before, during and after completion of ATT. Methods. Human immunodeficiency virus negative subjects with smear-positive drug-susceptible PTB were enrolled prior to initiation of ATT at the Grady Memorial Hospital, Atlanta, Georgia and followed longitudinally during ATT. ATT was provided according to national guidelines. Blood samples were obtained at baseline and during ATT. Peripheral blood mononuclear cells (PBMC) and plasma were isolated for each patient at each time point. Plasma IP-10 levels were measured by ELISA. Results. All patients achieved sputum culture-conversion and were considered cured. In plasma samples for four patients tested to date, IP-10 levels decreased with ATT. The decrease in IP-10 mirrored decreases in frequencies of CD38+, HLA-DR+, and Ki-67+M. tuberculosis-specific CD4+IFN-γ+ T cells. These markers of T cell activation and proliferation were previously shown by our group to be biomarkers of treatment response. Conclusion. In our limited sample set, the trend of decreasing plasma IP-10 during ATT appears to mirror the decrease in M. tuberculosis specific T cell markers of treatment response. Disclosures. All authors: No reported disclosures.
Source: Open Forum Infectious Diseases
Language: English
Subfield: Infectious Diseases
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $4,053
OpenAlex ID: W2294398257